Stryker (SYK) Stock Forecast & Price Target

Q: What analysts cover Stryker?

Stryker has been rated by research analysts at Argus , BMO Capital Markets , BTIG Research , Citigroup , Citizens Jmp , Evercore , JPMorgan Chase & Co. , Leerink Partners , Piper Sandler , Raymond James Financial , Royal Bank Of Canada , Truist Financial , UBS Group , Weiss Ratings , and Wolfe Research in the past 90 days.

$345.05 +6.02 (+1.78%)

Closing price 08/10/2026 03:58 PM Eastern

Extended Trading

$345.00 -0.05 (-0.01%)

As of 04:49 AM Eastern

Compare

Stryker - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 23 Analyst Ratings

Sell
0

Hold
5

Buy
18

Based on 23 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 5 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for SYK.

Consensus Price Target

$386.28
11.95% Upside

According to the 23 analysts' twelve-month price targets for Stryker, the average price target is $386.28. The highest price target for SYK is $465.00, while the lowest price target for SYK is $315.00. The average price target represents a forecasted upside of 11.95% from the current price of $345.05.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYK Analyst Ratings Over Time

Type	Current Forecast 8/11/25 to 8/11/26	1 Month Ago 7/12/25 to 7/12/26	3 Months Ago 5/13/25 to 5/13/26	1 Year Ago 8/11/24 to 8/11/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)	15 Buy rating(s)
Hold	5 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$386.28	$392.87	$395.48	$430.10
Forecasted Upside	11.95% Upside	19.10% Upside	30.89% Upside	14.16% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Stryker Stock vs. The Competition

Type	Stryker	Healthcare Companies	Broader Market
Consensus Rating Score	2.83	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	11.95% Upside	866.58% Upside	11.92% Upside
News Sentiment Rating	Positive News See Recent SYK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/3/2026	Citigroup 4 of 5 stars	Joanne Wuensch 2 of 5 stars	Reiterated Rating	Outperform
8/3/2026	Citizens Jmp 4 of 5 stars	David Turkaly 3 of 5 stars	Lower Target	Market Outperform	$440.00 ➝ $400.00	+19.13%
7/31/2026	Weiss Ratings 5 of 5 stars		Reiterated Rating	Hold (C)
7/31/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kendall Au Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$435.00 ➝ $420.00	+30.93%
7/31/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$370.00	+15.35%
7/31/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt O'Brien Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$420.00 ➝ $390.00	+11.95%
7/31/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$375.00	+7.64%
7/31/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$400.00 ➝ $350.00	+7.71%
7/31/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$330.00 ➝ $340.00	+5.29%
7/31/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$371.00 ➝ $358.00	+2.76%
Get the Latest News and Ratings for SYK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter.
7/28/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$400.00	+18.58%
7/9/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$370.00	+12.96%
7/8/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Market Perform ➝ Outperform	$369.00	+12.79%
7/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$350.00	+8.72%
6/5/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$410.00 ➝ $407.00	+35.30%
5/4/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$469.00 ➝ $394.00	+33.36%
5/1/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$361.00	+22.19%
5/1/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$410.00	+35.16%
5/1/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$385.00	+27.40%
5/1/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$315.00	+1.65%
5/1/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kyle Rose Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$435.00 ➝ $400.00	+35.39%
5/1/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$456.00 ➝ $418.00	+35.99%
5/1/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$454.00 ➝ $418.00	+32.85%
3/5/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
3/4/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$465.00	+21.57%
1/26/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$387.00	+8.35%
9/18/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$420.00	+11.54%
5/2/2025	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Wittes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$405.00 ➝ $456.00	+20.75%
1/29/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$400.00 ➝ $440.00	+11.41%
12/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$370.00 ➝ $445.00	+13.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:06 AM ET.

Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, August 8, 2026. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

Here are some ways that investors could benefit from investing in Stryker Co.:

The company has demonstrated strong financial performance, with a revenue increase of approximately 9.4% year-over-year, indicating robust demand for its medical technology products.
Stryker Co. has a solid cash position, ending the quarter with around $3.5 billion in cash and marketable securities, which provides flexibility for future investments and acquisitions.
The current stock price is around $X, reflecting a valuation that some analysts believe is attractive given the company's growth potential in the medtech sector.
With a dividend yield of 1.1% and a payout ratio of approximately 40.74%, Stryker Co. offers a reliable income stream for investors while maintaining a balance for reinvestment in growth opportunities.
The company plans to resume share repurchases, which can enhance shareholder value by reducing the number of outstanding shares, potentially increasing earnings per share (EPS).

Stryker
Bear Case

Investors should be bearish about investing in Stryker Co. for these reasons:

There are ongoing pressures related to oil and other raw materials, which could impact production costs and profit margins in the future.
Despite positive revenue growth, the medtech sector is experiencing valuation compression, which may affect stock performance and investor sentiment.
Acquisition opportunities may dictate the amount of capital allocated for share repurchases, leading to uncertainty in the timing and scale of buybacks.
Analysts predict an EPS of 14.99 for the current fiscal year, which, while positive, may not meet the higher expectations set by previous performance.
Market conditions and competition in the medical technology field could pose risks to Stryker Co.'s growth trajectory and market share.

SYK Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $386.28, with a high forecast of $465.00 and a low forecast of $315.00.

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last twelve months. There are currently 5 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SYK shares.

According to analysts, Stryker's stock has a predicted upside of 11.95% based on their 12-month stock forecasts.

Over the previous 90 days, Stryker's stock had 1 upgrade by analysts.

Stryker has been rated by research analysts at Argus, BMO Capital Markets, BTIG Research, Citigroup, Citizens Jmp, Evercore, JPMorgan Chase & Co., Leerink Partners, Piper Sandler, Raymond James Financial, Royal Bank Of Canada, Truist Financial, UBS Group, Weiss Ratings, and Wolfe Research in the past 90 days.

Analysts like Stryker more than other "healthcare" companies. The consensus rating for Stryker is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how SYK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Stryker Recommendations

This page (NYSE:SYK) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stryker (SYK) Stock Forecast & Price Target